Examkin

Soru

Zorluk: ZorMenstrual Cycle Abnormalities and Contraception

A 3838-year-old G2P2 woman comes to the office seeking a reliable method of contraception. She also reports that over the past 88 months, her menstrual periods have become increasingly heavy. She states that her menses last for 77 to 88 days and she frequently soaks through a thick pad every 22 hours on the heaviest days. Her menstrual cycles remain regular, occurring every 2828 days. Her medical history is significant for frequent migraines with aura since age 2020. She smokes one pack of cigarettes daily. Her only medication is sumatriptan as needed. Vital signs include a blood pressure of 118/76 mmHg118/76 \text{ mmHg}, pulse of 72/min72\text{/min}, and BMI of 23 kg/m223 \text{ kg/m}^2. Pelvic examination reveals a normal-sized, mobile uterus without adnexal masses. A urine pregnancy test is negative. Laboratory studies show a hemoglobin of 10.8 g/dL10.8 \text{ g/dL} and a normal thyroid-stimulating hormone level. Which of the following is the most appropriate next step in management?

  1. Placement of a levonorgestrel-releasing intrauterine deviceCevap
  2. B
    Prescription of an ethinyl estradiol and etonogestrel vaginal ring
  3. C
    Endometrial biopsy
  4. D
    Measurement of serum free thyroxine
  5. E
    Measurement of serum total testosterone

Cevap

Placement of a levonorgestrel-releasing intrauterine device
This patient requires contraception and management of heavy menstrual bleeding. The levonorgestrel-releasing intrauterine device (LNG-IUD) is the most appropriate choice because it provides highly effective, long-acting contraception and is considered first-line medical therapy for heavy menstrual bleeding. The progestin in the IUD causes endometrial atrophy, significantly reducing menstrual blood loss and treating her underlying anemia. Furthermore, her history of migraines with aura and smoking at age 38 are both independent, absolute contraindications (WHO Medical Eligibility Criteria category 4) to any estrogen-containing contraceptive due to the unacceptably high risk of ischemic stroke and thromboembolism. Progestin-only methods like the LNG-IUD remain safe for this demographic.

Adım Adım Çözüm

1
Identify the patient's primary clinical needs from the presentation.
The patient requires highly effective contraception and medical management for regular but heavy menstrual bleeding complicated by mild anemia.
Addressing all chief complaints ensures comprehensive and appropriate patient care.
2
Evaluate the patient's medical history against the WHO Medical Eligibility Criteria (MEC) for contraceptive use.
The patient has migraines with aura and is a smoker aged 35 or older. Both conditions are Category 4 (unacceptable health risk) for combined hormonal contraceptives (estrogen-containing methods).
Exogenous estrogen significantly increases the risk of ischemic stroke and deep vein thrombosis in patients with these specific cardiovascular and neurologic risk factors.
3
Assess the remaining contraceptive options for their ability to manage heavy menstrual bleeding.
Non-estrogen methods (progestin-only pills, implants, IUDs) are safe. Among these, the levonorgestrel-releasing IUD is the most effective at thinning the endometrium and reducing menstrual blood loss.
A copper IUD would provide safe contraception but is contraindicated for heavy menstrual bleeding as it can exacerbate the condition.
4
Determine if further diagnostic testing is required before initiating therapy.
No further testing is needed. She is under 45 with no risk factors for endometrial cancer (normal BMI, regular cycles), so biopsy is not indicated. Her TSH is normal, ruling out primary thyroid dysfunction.
Avoiding unnecessary invasive procedures or redundant laboratory testing is a key component of high-value care.

Anahtar Kavram

Medical Eligibility Criteria for Contraceptive Use and Management of Heavy Menstrual Bleeding
Bu soruyu puanla

Konular

Menstrual Cycle Abnormalities and Contraception

Bu konudan daha fazla soru